IP Library Granted Patent US 9,801,752
Granted Patent B2
US 9,801,752 · App. 15/215,762 · Granted Oct 31, 2017

Post nasal drip treatment

Inventors: Scott J. Wolf (Menlo Park, CA); Andrew Frazier (Sunnyvale, CA)
Assignee: AERIN MEDICAL, INC.
A61F5/08A61B18/02A61B18/1442A61B18/1485A61B18/16A61M25/10A61B2018/00005A61B2018/0022A61B2018/00023A61B2018/00327A61B2018/00577A61B2018/00595A61B2018/00702A61B2018/00821A61B2018/00922A61B2018/00994A61B2018/0225A61B2018/0293A61B2018/143A61B2018/1425A61M2025/105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,801,752
App. No.
15/215,762
Granted
Oct 31, 2017
Kind
B2
Abstract

Systems and methods for treating a patient's mucus hypersecretion condition are disclosed herein. Certain implementations may involve a method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough. The method may include advancing a treatment delivery portion of an energy-based treatment device into a nostril of the patient. The treatment delivery portion may contact mucosal tissue of the upper airway without piercing the mucosal tissue. The treatment delivery portion may deliver treatment to at least one tissue selected from the group of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

Claims (43)

1. A method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough, the method comprising:

advancing a treatment delivery portion of a cryotherapy treatment device into a nostril of the patient;

contacting mucosal tissue of the upper airway with the treatment delivery portion, without piercing the mucosal tissue; and

delivering cryogenic cooling from the treatment delivery portion to cool a target tissue selected from the group consisting of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the target tissue and thus treat at least one of post nasal drip or chronic cough in the patient.

2. The method of claim 1 , wherein the treatment is delivered without forming an incision in the mucosal tissue and without delivering an implant.

3. The method of claim 1 , wherein the target tissue comprises nerve tissue underlying the mucosal tissue, and wherein delivering the cryogenic cooling comprises ablating the nerve tissue.

4. The method of claim 1 , further comprising measuring a temperature of the mucosal tissue using a thermocouple on the treatment delivery portion.

5. The method of claim 4 , further comprising adjusting an amount of delivered cryogenic cooling, at least partially in response to the measured temperature.

6. The method of claim 1 , further comprising injecting a polymerizing liquid before delivering the cryogenic cooling.

7. The method of claim 1 , wherein delivering the cryogenic cooling comprises injuring the target tissue.

8. The method of claim 7 , wherein delivering the treatment comprises injuring goblet cells that are part of the mucosal tissue.

9. The method of claim 7 , wherein the target tissue is selected from the group consisting of cilia, goblet cells, nerves, submucosal tissue, muscle, ligaments, cartilage, tendon, and skin.

10. The method of claim 1 , further comprising mechanically altering the mucosal tissue while delivering the cryogenic cooling.

11. The method of claim 1 , wherein delivering the cryogenic cooling comprises modifying the target tissue in a manner that decreases a volumetric rate of mucus production of the mucosal tissue without changing a shape of the mucosal tissue.

12. The method of claim 1 , wherein the cryogenic cooling is delivered to at least one turbinate of the upper airway.

13. The method of claim 12 , wherein the at least one turbinate comprises a posterior aspect of an inferior turbinate.

14. A device for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough, the device comprising:

an elongate shaft having a proximal end and a distal end;

a handle at the proximal end of the elongate shaft; and

a treatment portion at the distal end of the elongate shaft, the treatment portion comprising a treatment surface, the treatment surface comprising:

at least two energy delivery members extending longitudinally along the treatment surface; and

a temperature sensing member extending longitudinally along the treatment surface and separating the at least two energy delivery members.

15. The device of claim 14 , wherein the at least two energy delivery members comprise at least one positive electrode on one side of the temperature sensing member and at least one negative electrode on an opposite side of the temperature sensing member.

16. The device of claim 15 , wherein the at least one positive electrode comprises a first row of positive electrodes, and wherein the at least one negative electrode comprises a second row of negative electrodes.

17. The device of claim 16 , wherein the electrodes protrude from the treatment surface.

18. The device of claim 17 , wherein the electrodes are blunt-tipped electrodes.

19. The device of claim 17 , wherein the first row and the second row are curved.

20. The device of claim 14 , wherein the temperature sensing member comprises a thermocouple.

21. A method for reducing mucus secretion in an upper airway of a patient to treat at least one of post nasal drip or chronic cough, the method comprising:

advancing a treatment portion of the treatment device into a nostril of the patient to contact a treatment surface of the treatment portion with mucosal tissue of the upper airway, without piercing the mucosal tissue;

delivering radiofrequency energy from a first electrode on the treatment surface across a temperature sensing member in the treatment surface to a second electrode on the treatment surface to treat at least one tissue selected from the group consisting of the mucosal tissue and another tissue underlying the mucosal tissue to modify a property of the at least one tissue and thus treat at least one of post nasal drip or chronic cough in the patient;

measuring an amount of the radiofrequency energy delivered, using the temperature sensing member; and

removing the treatment portion from the upper airway without leaving an implant in the upper airway.

22. The method of claim 21 , further comprising performing a test to determine whether a desired contact between the treatment surface and the mucosal tissue has been achieved.

23. The method of claim 21 , wherein the delivering and measuring steps comprise:

delivering a first amount of the radiofrequency energy from the first electrode to the second electrode;

measuring a temperature of the mucosal tissue using the temperature sensing member; and

delivering a second amount of the radiofrequency energy from the first electrode to the second electrode, wherein the second amount of radiofrequency energy is based at least in part on the measured temperature.

24. The method of claim 21 , wherein the mucosal tissue comprises tissue located on at least one nasal turbinate of the upper airway.

25. The method of claim 24 , wherein the mucosal tissue comprises tissue located on a posterior aspect of an inferior turbinate.

26. The method of claim 24 , wherein delivering the radiofrequency energy results in a reduction in volume of the at least one nasal turbinate.

27. The method of claim 21 , wherein delivering the radiofrequency energy comprises delivering the radiofrequency energy in an amount that deactivates mucus producing cells by impairing at least one of mucus production ability or cell differentiation ability of the mucus producing cells.

28. The method of claim 21 , wherein delivering the radiofrequency energy comprises delivering the radiofrequency energy in an amount that causes one or more mucus paths of the upper airway to divert.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2024
From: CRG SERVICING LLC
To: AERIN MEDICAL INC.
Reel/Frame 069654/0467 →
SECURITY INTEREST Recorded Dec 20, 2024
From: AERIN MEDICAL INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 069746/0508 →
SECURITY INTEREST Recorded May 13, 2019
From: AERIN MEDICAL INC.
To: CRG SERVICING LLC
Reel/Frame 049161/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2019
From: WOLF, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL, INC.
Reel/Frame 048164/0699 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2017
From: WOLF, SCOTT J.; FRAZIER, ANDREW
To: AERIN MEDICAL, INC.
Reel/Frame 043524/0021 →
Continuity (7)
Continuation 14675689 · Mar 31, 2015
Continuation In Part 14319087 · Jun 30, 2014
Continuation In Part 13495844 · Jun 13, 2012
Provisional Application 61974534 · Apr 3, 2014
Provisional Application 61603864 · Feb 27, 2012
Provisional Application 61496930 · Jun 14, 2011
Related Publication 20170014258A1 · Jan 19, 2017